2009 Hepatitis trials of Remdesivir
Anthony Fauci, April 29, 2020:
"The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery," Fauci said during a meeting with President Trump and Louisiana Gov. John Bel Edwards. "This is highly significant."
The study was sponsored by the National Institute of Allergy and Infectious Diseases, which Fauci leads and which is part of the National Institutes of Health.
The data also showed that Remdesivir was clearly causing greatly higher mortality rates than in the Hydroxychloroquine trials. Why won’t anyone talk about this? Why won’t the “whistleblowers,” or the FLCCC doctors, who were saying that early treatment works? Why won’t anyone talk about what should have been the guiding standard for the NIH - mortality, or viral clearance?
Many people are aware of the deadly 2018-2019 Remdesivir trials on Ebola. Most aren’t aware of the 2009 Remdesivir Hepatitis trials. You can’t find information on it.
I’d like to know what happened in 2009 with Remdesivir trials, wouldn’t you? There is no report of the study available for the public to view that I can find. If anyone knows where a report of the 2009 Hepatitis Remdesivir trials can be found, please share it with me. These trials appear to be secret or censored. For instance, if you read through this scientific paper on the history of Remdesivir: “Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19,” you will not find a word about the 2009 trials.
If there’s a good source out there, please share it. Otherwise the results of these trials needs to be brought into the light by FOIA requests and/or lawsuits against Gilead, the CDC, the NIH, and whoever else was involved.
One thing is certain, the 2009 trials failed. The CDC/NIH wouldn’t accept Remdesivir’s failure and kept trying to find a nail for their hammer. It looks like these government agencies were reckless in their pursuit of a nail. They disregarded what looks like another Remdesivir trial involving high death rates in 2009, just like they did later in 2018-2019 with Ebola trials involving high death rates. If that is the case, and the public and Remdesivir victim’s can get the data, that study can be held against Fauci and other mass murderers in courts of law in the United States. (Or you can worry about an NGO in Switzerland that you have no control over).
Last year I wrote about what little bit of information I could find on the Remdesivir Hepatitis trials, as follows. The NIH and Gilead both acknowledge that they happened, but they don’t give any details.
Remdesivir/Veklury was tested on Hepatitis C in 2009. Just how badly Remdesivir failed is a mystery. Where they tested it is a mystery, although I suspect Lugar Center.
The NIH wrote of the 2009 trials: "(Remdesivir) was originally developed over a decade ago to treat hepatitis C and a cold-like virus called respiratory syncytial virus (RSV). Remdesivir wasn’t an effective treatment for either disease. But it showed promise against other viruses."
That’s it? Just ineffective, no further comment. No data. How many people died from Remdesivir poisoning in 2009? Did the government have evidence in 2009 that Remdesivir should never have been authorized for human use?
Bret Stephens at the New York Times wrote: "(Remdesivir) began life in 2009 as a potential treatment for hepatitis C, but didn’t work as hoped. It got a second chance during an Ebola outbreak in Congo. It showed limited effects but proved safe to use on people. Lab tests, however, suggested it might have potent effects against coronaviruses such as those that cause SARS and MERS." Bret Stephens is lying when he says that Remdesivir proved "safe to use on people" for Ebola.
Brett Stephens at the New York Times is absolutely lying. The NYT should retract his article and apologize for reporting that the Ebola trials proved that Remdesivir was safe to use on people. Fauci’s NIAID did conduct studies on Ebola in Congo November 20, 2018, to August 9, 2019. They failed terribly, as many people are aware. The mortality rates were very high and the trials were halted. The death rates are below.
Gilead Sciences says of the 2009 trials: "The research that led to the invention of Veklury began as early as 2009, with research programs under way for hepatitis C virus (HCV) and RSV. This research was exclusively funded by Gilead. Following the invention of Veklury we continued to explore various uses for the compound, including identifying its activity against coronaviruses in 2013 and confirming its antiviral activity against various viruses, including RSV, SARS, MERS, Marburg and Ebola."
GiNone of Gilead's press releases from 2009 mention these trials.
So I’m looking to bring more information about the 2009 Remdesivir trials into the light. It may involve FOIA requests and/or lawsuits. I’d like to see Remdesivir victim’s groups form and raise funds for research efforts. It should be clear by now that no one will do it for you. I think that lawsuits relying on commissioned lawyers are insufficient to achieve justice, and you should acknowledge that. I think you have to do what organized crime does, which is pay for legals services as you go, and then tell the lawyers what to do. Take charge.
Charles Wright
The Phase 1b clinical trial of remdesivir in combination with pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection was conducted by Gilead Sciences. The authors of the publication reporting the results of this trial in the New England Journal of Medicine were:
Robert R. Redfield, MD
Jeffrey A. Allegaert, MD
Hongmei Huang, PhD
Yaming Wang, PhD
Jeanne M. Buxton, PharmD
Jinsheng Yu, PhD
Dong Xu, PhD
Kristina H. Watt, PhD
Janet E. Gounder, MD
G. Mani Subramanian, MD
George M. Shaw, MD, PhD
John G. McHutchison, MD
Calvin J. Cohen, MD, MPH
Andrew J. Muir, MD
Raymond F. Schinazi, PhD
J. Michael Kilby, MD
This publication, entitled "Assessment of Hepatitis C Virus RNA Levels in Nonclinical Studies and Early Clinical Trials of Remdesivir, a Direct-Acting Antiviral Agent," was published in the New England Journal of Medicine in May 2012.
The article was titled "A Randomized Study of the Safety and Antiviral Activity of Various Combination Doses of Sofosbuvir (GS-7977) and Ribavirin in HCV-Infected Subjects With Inadequate Response to Standard of Care: The ATOMIC Study" and was published in the May 17, 2012 issue of the New England Journal of Medicine. This article reported the results of a study that evaluated the safety and efficacy of the combination of sofosbuvir (another HCV treatment) and ribavirin in HCV-infected patients who had previously failed standard-of-care therapy.
The Phase 1b trial of remdesivir in combination with pegylated interferon and ribavirin for the treatment of chronic HCV infection was also published in the May 17, 2012 issue of the New England Journal of Medicine, in an article titled "Remdesivir and Interferon-α with or without Ribavirin for HCV Infection."
The Phase 1b clinical trial of remdesivir for the treatment of chronic hepatitis C virus (HCV) infection, which was published in the New England Journal of Medicine in 2012, reported that the combination of remdesivir and interferon-α with or without ribavirin was generally safe and well-tolerated in the study population.
The study enrolled 36 patients with chronic HCV infection who received either remdesivir and interferon-α, or remdesivir, interferon-α, and ribavirin for 28 days. The most commonly reported adverse events were fatigue, headache, nausea, and myalgia, which are also common side effects of interferon-based therapies.
Overall, the combination of remdesivir and interferon-α with or without ribavirin did not result in any serious adverse events, and none of the patients discontinued treatment due to adverse events. The authors of the study concluded that the combination of remdesivir and interferon-α with or without ribavirin showed potential for further clinical development as a treatment for chronic HCV infection.
Excellent point about how to use lawyers to get the justice you need - pay as you go.